Skip to content
★ Sign in to follow
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. Stock: price and insider trades · China

益丰药房

CN·Mcap CN¥30.8BHealth Care

No insider purchase over the last 90 days. The latest, by 肖再祥, was filed 11 Dec 2023.

Yifeng Pharmacy Chain Co., Ltd.: what insiders have been doing

This page follows insider dealings at Yifeng Pharmacy Chain Co., Ltd. as filed with SSE / SZSE (CSRC), a company from the Health Care sector. Over the twelve months to 4 November 2026, 2 filings were filed, from 1 insider.

Only sales appear on the open market, 2 sales in all totalling €147k, filed by 1 insider. One trade stands out by size: a sale of €75k from 肖再祥, disclosed on 3 March 2026.

With 2 filings in twelve months, the company is in line with the median of 2 filings across the 517 companies we follow on the same exchange. Over the whole record (from 2021), the tally stands at 1 purchase and 6 sales.

Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.

For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and UCB. Source: insider filings from SSE / SZSE (CSRC). Past trades are no guide to future returns.

Insider Decl.
7
Thresholds
n/a
Buy Volume
€10,965
1 ops. · all time
Sell Volume
€59M
6 ops. · all time

Who traded when

BuySale
肖再祥2 sales
宁波梅山保税港区厚信创业投资合伙企业(有限合伙)1 sale
颜俊1 sale

Since the insiders bought

  • Filed 11 Dec 2023 · 1063 days ago · €11k
    -34.3%
    Entry CN¥37.02 · Close at T+365 CN¥24.33

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 4,532 of 26,912 companies
69.0
score / 100
Value
71
Quality
67
FCF yld9.9%
Earn yld5.5%
EV/EBITDA8.0x
ROE16%
Gross mgn39%
Net mgn6.9%
Debt/EBITDA1.0x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥25.37
Analyst consensus
13 analysts
·
CN¥22.50Target CN¥31.37(+24%)CN¥43.28
Income statement
RevenueCN¥24.4B
Gross profitCN¥9.6B39% margin
EBITDACN¥4.4B18% margin
Net incomeCN¥1.7B7.1% margin
Valuation
PER (trailing)17.5x
PER (forward)13.8x
P/Book2.5x
Beta0.26
Balance sheet & cash
Market capCN¥30.8B
Total debtCN¥4.4B
Free Cash FlowCN¥3B
Debt / Equity32%
Profitability & ownership
ROE15.7%
ROA6.1%
% insiders52.8%
% institutions11.9%
Last declaration on 5 March 2026
Declarations7 total
  • ▼
    高级管理人员Executives
    581,000 CNY16SSE
    25,000 shares45.7% of flowA股XSHGSSE:273000000231958100
  • ▼
    高级管理人员Executives
    603,300 CNY16SSE
    25,000 shares47.3% of flowA股XSHGSSE:273000000231958270
  • ▼
    491M CNY30SSE
    21,471,900 shares100.0% of flowA股XSHGSSE:173000009320124640
  • ▼
    高级管理人员Executives
    572,958 CNY19SSE
    22,900 shares100.0% of flowA股XSHGSSE:173000008719093000
  • ▲
    高级管理人员Executives
    84,732 CNY12SSE
    2,300 shares6.9% of flowA股XSHGSSE:173000007162398080
    Canonical exit: 10 Mar 2024 (T+90)
  • ▼
    董事,副总裁Executives
    555,000 CNY42SSE
    10,000 shares100.0% of flowA股XSHGSSE:173000005475766180
  • ▼
    董事Executives
    261,000 CNY15SSE
    5,000 shares100.0% of flowA股XSHGSSE:173000005170418100

7 of 7 declarations

About Yifeng Pharmacy Chain Co., Ltd.

益丰药房 is a pharmacy chain in China, specializing in the sale of medications and health products. It primarily operates in the healthcare and pharmaceutical market.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations